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Regarding “Long-term results of stent graft
treatment of subclavian artery injuries: Management
of choice for stable patients?”
We read with interest the article regarding stent graft treat-
ment of 57 traumatic sublcavian arterial injuries.1 It is surprising
that no mention was made of the vertebral artery. Certainly with
stent grafts varying from 30 to 60 mm in length, the vertebral
artery was covered in many (if not most) of their cases. If this is
true, did they first determine if the contralateral vertebral artery
was patent all the way to the basilar artery? After all, a hypoplastic
vertebral artery is an uncommon, but real, entity. The authors
reported that they treated 39% of their subclavian injuries with
stent grafts and believe that up to 50% of such injuries could be
treated in this fashion. Does proximity of the subclavian injury to
the vertebral artery origin play a role in the 50% who cannot be
treated endovascularly?
Also of interest is the statement that a stent graft cannot be
used if there is much of a difference in arterial diameters at the
proximal and distal landing zones. Except for their 12 cases of
arteriovenous fistulae, the diameter of a subclavian artery should
not change much from proximal to distal. Even if it did, Fluency
stent grafts (Bard, Tempe, Arizona) have been shown to have
minimal infolding when oversized up to 3 mm relative to the
vessel. How often would proximal to distal subclavian diameter
ever be a problem?
Overall, we found this series of 57 subclavian arterial injuries
treated endovascularly without limb loss or other incapacitating
symptoms to be impressive. However, we would like to have seen
a discussion of the vertebral artery and believe that proximal and
distal luminal discrepancy of the subclavian artery would be a rare
contraindication to stent graft placement.
Douglas C. Smith, MD
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We appreciate the interest of Drs Smith and Carlson in our
article reporting the long-term results of stent graft treatment of
subclavian artery injuries.1 We thank them for the 2 interesting
comments. We did not describe all the technical details of the
procedure but did refer to our previously published article2 where
the issue of the vertebral artery was discussed. We did cover the
vertebral artery in many of the cases after confirming by angiogra-
phy that a patent normal sized contra lateral vertebral artery with
good cross flow into the Circle of Willis was present. No neuro-
logical complications were encountered as a result of this approach.
Although the reported incidence of congenital atresia or hypopla-
sia of one vertebral artery is 2%-3%,3 we did not exclude any patient
from endovascular treatment on the basis of this finding. We agree
that it might be a rare contraindication to stent graft treatment if
encountered on the contra lateral side to the injury.
We agree that luminal discrepancy is a rare contraindication to
stent graft treatment. However, 2 of the 4 patients that were
excluded from endovascular treatment on the basis of radiological
findings had a difference between proximal and distal arterial
diameters of more than 5 mm. They both presented with a chronic
arteriovenous fistula, respectively 7 and 10 years after injury, with
massively dilated proximal and small atrophic distal arteries. This
discrepancy was regarded as incompatible with successful endovas-
cular treatment and we were forced to treat them with open
surgery.
We thank Drs Smith and Carlson for focusing the attention on
these 2 issues.
Daniel F. du Toit, MD
Anton V. Lambrechts, MD
Department of Surgery
University of Stellenbosch
Tygerberg Hospital
Tygerberg, South Africa
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Regarding “Reference value of transcutaneous oxygen
measurement in diabetic patients compared with
nondiabetic patients”
We read with great interest the article of deMeijer et al1 about
the values of transcutaneous oxygen pressure (TcPO2) measure-
ments in diabetic compared with nondiabetic patients. The authors
found a 6-mm Hg difference in the mean chest and main foot
TcPO2 values between diabetic and nondiabetic subjects with
apparently no peripheral arterial disease. The authors suggest in
their conclusion that resting TcPO2 could be proposed as an
additional tool in the diagnostic armamentarium of vascular sur-
geons to assess peripheral vascular disease in diabetic patients.
First, there might be a lot of reasons (skin thickness, use of
vasoactive drugs) other than vascular disease that could modify
TcPO values. It is also not unlikely that the difference observed2
resulted from vascular dysfunction rather than from vascular dis-
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diabetic patients to local heating is impaired,2 and it should be kept
in mind that TcPO2 is measured at 43°C and then automatically
corrected to 37°C.
Second, the standard deviations (SD) of TcPO2 are similar in the
two groups: 11 to 12 mmHg at the chest and 9 mmHg at the foot.
Then the differences between means found between diabetic and
nondiabetic subjects are roughly 0.50 SD at the chest and 0.66 SD at
the foot level. For an equal cost of false-positive and false-negative
tests,mathematically the optimal cutoff point for the discriminationof
the two clinical situations would be half way between the two means
(according to the authors’ results, 55mmHg at the chest and 53mm
Hg at the foot). In a Gaussian distribution, only 20% and 26% of a
population are in the interval mean 0.25 SD andmean 0.33 SD,
respectively.3 Then if TcPO2 should be used as a tool to assess vascular
disease or dysfunction, the sensitivity and specificity of TcPO2 would
both be 60% and 63% at the chest and foot level, respectively. Assum-
ing that the prevalence of diabetes in the population is 10% in
Europe,4 the positive predictive values of a chest TcPO255mmHg
and a foot TcPO253mmHg to detect a diabetic vascular disease or
dysfunction in the population would be12% and 15%, respectively.
Third, as underlined by the authors, TcPO2 is primarily used as
a key point for the diagnosis of critical limb ischemia, amputation
level determination, and wound healing evaluation. Thus, there
are two major issues resulting from this article. The first issue is to
define whether the difference in chest TcPO2 can be found in a
population of patients referred for critical limb ischemia. The
second issue is that in diabetes, a number of factors, including
neuropathy, may induce foot lesions independently from the pres-
ence of arterial disease. Thus, contrary to the chest TcPO2 and due
to a higher prevalence of foot lesions unrelated to vascular disease,
the foot TcPO2 in diabetic patients with suspected foot ulcer or
critical limb ischemia could on the average be higher than in
nondiabetic subjects.
Thereby, although the difference between the two groups is
significant, we think that the discriminative power of the sole
resting value for TcPO2 is insufficient to be useful in clinical
practice as an additional diagnostic tool to assess subclinical periph-
eral vascular disease of diabetic origin.
Vincent Jaquinandi, MD, PhD
Guillaume Mahe, MD
Georges Leftheriotis, MD, PhD
Jean Louis Saumet, MD, PhD
Pierre Abraham, MD, PhD
University Hospital
Angers, France
REFERENCES
1. de Meijer VE, Van’t Sant HP, Spronk S, Kusters FJ, den Hoed PT.
Reference value of transcutaneous oxygen measurement in diabetic pa-
tients compared with nondiabetic patients. J Vasc Surg 2008;48:382-8.
2. Boyko EJ, Ahroni JH, Stensel VL. Tissue oxygenation and skin blood
flow in the diabetic foot: responses to cutaneous warming. Foot Ankle Int
2001;22:711-4.
3. Fisher RA, Yates FA. Statistical tables for biological, agricultural, and
medical research. Edinburgh, UK: Oliver and Boyd; 1938.
4. Virally M, Blicklé JF, Girard J, Halimi S, Simon D, Guillausseau PJ. Type
2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and
therapeutical perspectives. Diabetes Metab 2007;33:231-44.
doi:10.1016/j.jvs.2008.08.109
Reply
We thank Jaquinandi et al for commenting on our research
article “Reference value of transcutaneous oxygen measurement in
diabetic patients compared to non-diabetic patients.”1We agree that one should always be aware that confounding
factors might have modified the outcome. To prevent bias from
confounding, we matched the study groups for age and sex.
Furthermore, we controlled for several possible confounding
variables using multivariate analysis. Although not recorded,
skin thickness and use of vasoactive drugs may influence TcPO2
measurements but are unlikely to have been significantly differ-
ent in both groups. In contrast to what Jaquinandi et al wrote,
we concluded that subclinical microvascular impairment was
responsible for the observed differences in TcPO2 outcome, and
not vascular disease. We therefore acknowledge the impaired
reactivity of diabetic patients to local heating, which could be a
result from vascular dysfunction in their skin microcirculation.
Second, we did not propose TcPO2 measurement as a distinc-
tive modality to detect diabetic vascular disease or dysfunction in
the general population, but as an additional diagnostic tool that
may be helpful to detect occult microvascular dysfunction in
diabetic patients at risk for peripheral vascular disease. It has been
shown that TcPO2 measurement can be a useful modality to
prevent peripheral vascular disease in diabetic patients because it
allows detection of early changes in skin oxygenation before the
development of clinically overt microangiopathy.2
Although the theoretic values for sensitivity and specificity
may have been well calculated by Jaquinandi et al to compare
the discriminative capacity of TcPO2 measurement between
diabetic and nondiabetic patients, this was not our research
objective. Moreover, we believe that calculating a positive pre-
dictive value (PPV) to detect a diabetic vascular disease or
dysfunction in the general population from our results, at best,
can be considered overstretched. We do not think it is justified
to calculate sensitivity, specificity, or PPV for TcPO2 measure-
ment as a predictor for microvascular dysfunction in diabetic
patients because we cannot provide a rationale to pick a scien-
tifically based cutoff point.
Others, however, have previously investigated the use of
TcPO2 measurement as a predictor for outcome of diabetic foot
ulcers.3 They found that when using 25 mm Hg as a cutoff
point, TcPO2 measurement is a better predictor for ulcer healing
in diabetic patients (PPV, 79%) compared with toe blood pres-
sure (PPV, 67%). Instead of using TcPO2 measurement as a
discriminative screenings modality for diabetic vascular disease
or dysfunction, we would advocate to record consecutive results
on a per-patient basis to detect microvascular impairment and to
evaluate possible progression to peripheral vascular disease.
Further, Jaquinandi et al questioned whether the observed
difference in TcPO2 measurement at chest level between dia-
betic and nondiabetic patients could be found in a population of
patients referred for critical limb ischemia. Williams et al4
recently reported mean TcPO2 values (foot/chest) of 63/71
mm Hg for nondiabetic patients without vascular disease, and
63/60 mm Hg for nondiabetic patients with vascular disease.
Mean TcPO2 values for diabetic patients without or with vascu-
lar disease were 56/57 mm Hg and 57/53 mm Hg, respec-
tively. Although we do not have an explanation for the lower
TcPO2 values at the chest level of diabetic patients with or
without vascular disease, this study is in accordance with our
reported results.
We acknowledge their final comment that TcPO2 values at the
foot in diabetic patients with suspected foot ulcer or critical limb
ischemia could on the average be higher than in nondiabetic
patients. We have, however, not been able to investigate this
because all our participants were free of signs of both peripheral
disease and neuropathy.
According to our original research question, we believe that
consistent reference values for TcPO2 are crucial in order to evalu-
ate diabetic patients with a foot at risk, and we would like to
maintain our conclusion that the TcPO2 measurement may be a
useful additional diagnostic modality to detect subclinical micro-
vascular impairment in diabetic patients in order to monitor and
even prevent progression to peripheral vascular disease.
